REFERENCES
- Dillman R.O., Seagren S.L., Propert K.J., Guerra J., Eaton W.L., Perry M.C., Carey R.W., Frei E.F., 3rd;, Green M.R. A Randomized Trial of Induction Chemotherapy Plus High-Dose Radiation Versus Radiation Alone in Stage III Non-Small-Cell Lung Cancer. N. Engl. J. Med. 1990; 323: 940–945
- Rosell R., Gomez-Codina J., Camps C., Maestre J., Padille J., Canto A., Mate J.L., Li S., Roig J., Olazabal A. A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer. N. Engl. J. Med. 1994; 330: 153–158
- Fujiwara T., Grimm E.A., Mukhopadhyay T., Zhang W.W., Owen-Schaub L.B., Roth J.A. Induction of Chemosensitivity in Human Lung Cancer Cells In Vivo by Adenovirus-Mediated Transfer of the Wild Type p-53 Gene. Cancer Res. 1994; 54: 2287–2291
- Rusch V., Klimstra D., Venkatramen E., Oliver J., Martini N., Gralla R., Kris M., Dmitrovsky E. Aberrant p53 Expression Predicts Clinical Resistance to Cisplatin Based Chemotherapy in Locally Advanced Non Small Cell Lung Cancer. Cancer Res. 1995; 55: 5038–5042
- Sugarbaker D.J., Herndon J., Kohman L.J., Krasna M.J., Green M.R. Results of Cancer and Leukemia Group B Protocol 8935. A Multiinstitutional Phase II Trimodality Trial for Stage IIIA (N2) Non-Small-Cell Lung Cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J. Thorac. Cardiovasc. Surg. 1995; 109: 473–483
- Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents. Cell 1993; 74: 957–967
- Rusch V.W., Albain K.S., Crowley J.J., Rice T.W., Lonchyna V., McKenna R., Jr, Stelzer K., Livingston R.B. Neoadjuvant Therapy: A Novel and Effective Treatment for Stage IIIb Non-Small Cell Lung Cancer. Ann. Thorac. Surg. 1994; 58: 290–295
- Roth J.A., Fosella F., Komaki R., Ryan M.B., Putnam JB, Jr, Lee JS, Dhingra H., De Caro L., Chasen M., McGavran M. A Randomized Trial Comparing Perioperative Chemotherapy and Surgery with Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung Cancer. J. Natl Cancer Inst. 1994; 86: 673–680
- Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 Is Required for Radiation-Induced Apoptosis in Mouth Thymocytes. Nature 1993; 362: 847–849
- Harpole D.H., Herndon J.E., II, Wolfe W.G., Iglehart J.D., Marks J.R. A Prognostic Model of Recurrence and Death in Stage I Non-Small Cell Lung Cancer Utilizing Presentation, Histopathology, and Oncoprotein Expression. Cancer Res. 1995; 55: 51–56
- Carbone D.P., Mitsudomi T., Chiba I., Piantadosi S., Rusch V., Nowak J.A., McIntire D., Slamon D., Gazdar A., Minna J. p53 Immunostaining Positivity is Associated with Reduced Survival and Is Imperfectly Correlated with Gene Mutations in Resected Non-Small Cell Lung Cancer. A Preliminary Report of LCSG 871. Chest 1994; 106(Suppl. 6)377s–381s
- Isobe T., Hiyama K., Yoshida Y., Fujiwara Y., Yamakido M. Prognostic Significance of p53 and ras Gene Abnormalities in Lung Adenocarcinoma Patients with Stage I Disease After Curative Resection. Jpn. J. Cancer Res. 1994; 85: 1240–1246
- Lee J.S., Yoon A., Kalapurakal S.K., Ro JY, Lee J.J., Tu N., Hittelman W.N., Hong W.K. Prognostic Significance of p53 Oncoprotein in Non-Small-Cell Lung Cancer at a Favorable Prognostic Factor. J. Clin. Oncol. 1995; 13: 1893–1903
- Yu Y., Little J.B. p53 Is Involved in but not Required for Ionizing Radiation-Induced Caspase-3 Activation and Apoptosis in Human Lymphoblast Cell Lines. Cancer Res. 1998; 58: 4277–4281
- Ding H.F., Fisher D.E. Mechanisms of p53-Mediated Apoptosis. Crit. Rev. Oncol. 1998; 9: 83–98